SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)
The primary purpose of the study is to evaluate the efficacy (overall response) and safety of temozolomide in Step 1 at the dose and regimen approved in the US and the EU countries (28 day cycles of temozolomide at 150 to 200 mg/m2 once daily for 5 consecutive days with a 23 day rest period) in patients with anaplastic astrocytoma at first relapse.
Astrocytoma
DRUG: Temozolomide
Overall response in Step 1, 6 months|Incidence rate and severity of adverse events with administration of temozolomide in Step 1, 7 months (during temozolomide administration for 6 months and follow-up for 1 month)
Progression-free survival in Step 1, 6 months|Overall survival in Step 1, 6 months|Tumor response in Step 1, 6 months|Neurological improvement in Step 1, 6 months|Progression-free survival, overall survival, overall response, effect on neurological symptoms, and safety in Step 2, 6 months|Progression-free survival in Step 2, Up to 2 years|Overall survival in Step 2, Up to 2 years|Overall response in Step 2, Up to 2 years|Effect on neurological symptoms in Step 2, Up to 2 years|Safety in Step 2, Up to 2 years
The primary purpose of the study is to evaluate the efficacy (overall response) and safety of temozolomide in Step 1 at the dose and regimen approved in the US and the EU countries (28 day cycles of temozolomide at 150 to 200 mg/m2 once daily for 5 consecutive days with a 23 day rest period) in patients with anaplastic astrocytoma at first relapse.